Clinical Trials Logo

Disease clinical trials

View clinical trials related to Disease.

Filter by:

NCT ID: NCT03564132 Completed - Tic Disorders Clinical Trials

Evaluating the Efficacy and Safety of Yi-Gan San in Children and Adolescents With Tourette's Disorder

Start date: June 16, 2018
Phase: Phase 2
Study type: Interventional

Yigansan was used in Ming dynasty by Xue Kai as a remedy for restlessness and agitation in children. We expect that the total YGTSS scores of Yigansan-treated subjects will be significantly reduced compared to that of placebo-treated subjects.

NCT ID: NCT03560570 Completed - Clinical trials for Congenital Disorders of Glycosylation

Study of Hemostasis in Patients With Congenital Disorder of Glycosylation

CDG-Coag
Start date: January 1, 2014
Phase:
Study type: Observational

The purpose of this study is to investigate the coagulation balance in a cohort of congenital disorder of glycosylation (CDG) patients using conventional tests combined with an integrated approach of their coagulation disorders in using TGA in the absence or presence of sTM. Thus, investigators aimed to define if the hemostatic balance in CDG patients, is preserved despite of combined deficiencies in both procoagulant and anticoagulant factors.

NCT ID: NCT03560453 Completed - Clinical trials for Autism Spectrum Disorder

Facilitating Employment for Youth With Autism

Start date: August 1, 2013
Phase: N/A
Study type: Interventional

This study will test the efficacy of a nationally recognized employment training and placement program (Project SEARCH) when applied to youth with Autism Spectrum Disorders. It is designed to examine a single overall research question: Research Question: To what extent does a collaborative, employer-based employment training and placement program improve the employment outcomes, need for support, social responsiveness, self-determination, and quality of life of young adults with ASD 18-21 served in public special education programs?

NCT ID: NCT03559426 Completed - Schizophrenia Clinical Trials

Research Into Antipsychotic Discontinuation and Reduction Trial

Start date: March 24, 2016
Phase: Phase 4
Study type: Interventional

Psychosis and schizophrenia are common and costly mental health problems. Psychosis is the name given to a group of mental conditions in which cause people to perceive or interpret things differently from those around them. One of the most common causes of psychosis is schizophrenia, a condition that causes a range of psychological symptoms, including hallucinations (hearing and/or seeing things) and delusions (believing something that is not true). One of the main treatment options for psychosis and schizophrenia is long-term treatment with antipsychotic medication, but many patients still find life difficult. Antipsychotic drugs can also have dangerous and unpleasant side effects. Finding alternatives to long-term drug treatment is a priority for patients and services. This study is testing the effects of gradually reducing antipsychotic medication in people with schizophrenia, psychosis or similar conditions in order to see if it can help improve day-to-day functioning and how it affects their chance of suffering a relapse (worsening of their condition).

NCT ID: NCT03558529 Completed - Schizophrenia Clinical Trials

Feasibility and Acceptability of a Smartphone App to Assess Early Warning Signs of Psychosis Relapse

ExPRESS:2
Start date: May 1, 2015
Phase:
Study type: Observational

About 1 in 100 people will experience an episode of psychosis. Some people will only experience one 'psychotic episode' and about a quarter of people make a full recovery. Others will have recurring periods of problems ('relapses'), perhaps at times of particular stress. As people often find psychosis distressing, this study looks at ways to help them stay well in the future. There is growing evidence that 'early signs' interventions can prevent relapses of psychosis. Early signs are things that might happen when people start to become unwell. For example some people start to sleep badly when they are becoming unwell. Most people with psychosis can identify early signs emerging in the weeks before relapse. In early signs interventions, service users are taught to recognise early signs that their mental health may be deteriorating so that they can take action to avoid becoming unwell. Although early signs interventions show promise, the investigators suggest that they can be improved by more accurate assessment of relapse risk. This might be achieved by monitoring 'basic symptoms' in addition to conventional early signs of relapse. Basic symptoms are subtle, subclinical disturbances in one's experience of oneself and the world. Typical basic symptoms include: changes in perceptions, such as increased vividness of colour vision; impaired tolerance to certain stressors; difficulty finding or understanding common words. In this study the investigators want to design and test a mobile phone app to help monitor basic symptoms. They hope that the app might help service users to stay well in the future. During the study the investigators will ask participants to use the app once a week for 6 months. At the end of the study they will interview them about their experiences of using the phone app and participating in the study.

NCT ID: NCT03556878 Completed - Sleep Disorder Clinical Trials

Implementing and Sustaining a Transdiagnostic Sleep and Circadian Treatment

Start date: July 20, 2018
Phase: N/A
Study type: Interventional

The goal is to collect pilot data on an adapted version of the Transdiagnostic Sleep and Circadian intervention (TranS-C), referred to as 'Fitted TranS-C'.

NCT ID: NCT03556150 Completed - Clinical trials for Temporomandibular Disorder

Effectiveness of a Manual Therapy Protocol in Patients With Masticatory Muscle Disorders

Start date: June 15, 2018
Phase: N/A
Study type: Interventional

Comparing the efficiency between manual therapy protocol and effleurage in patients with temporomandibular disorders.

NCT ID: NCT03552510 Completed - Preterm Infant Clinical Trials

Oropharyngeal Administration of Mother's Milk in Preterm Infants and Gastrointestinal Motility

OPAMM
Start date: June 1, 2016
Phase: N/A
Study type: Interventional

Mother's milk does not come in contact with the oropharyngeal pouch of preterm infants during gavage feeding. We hypothesized that stimulation of the oropharyngeal pouch using small amount of the mother's milk 5 minutes before initiation of regular gavage feeding will increase the level of GIT hormones.

NCT ID: NCT03552068 Completed - Parkinson's Disease Clinical Trials

Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease:

ID-CLO
Start date: May 15, 2019
Phase: Phase 2
Study type: Interventional

Noradrenergic system is involved in impulsivity in the general population and is altered in Parkinson's disease (PD) in the early stages of the disease. Thus, targeting this system could be of interest in impulse control disorder (ICD). Acting on the noradrenergic system is possible using clonidine, an α2 adrenergic agonist largely used in hypertension treatment and that induces a decrease of NADR release. Thus, our aim is to conduct a proof of concept study evaluating the efficacy and safety of clonidine on ICD in PD. This study is a multicenter, randomized, double-blind, placebo-controlled in parallel group clinical trial.

NCT ID: NCT03550365 Completed - Inflammation Clinical Trials

Grain Fibre and Gut Health

FIBREFECTS
Start date: January 1, 2011
Phase: N/A
Study type: Interventional

Wholegrain fibre is known to affect on the gut health, but also may cause intestinal discomfort. Thus, many individuals may avoid the consumption of whole grain cereals in spite of their known health benefits, and may in this regard consume more restricted diets. In the preset study the aim was to technologically modify the cereal fibres to improve its usability and to maintain its health beneficial properties. The objective was to investigate intestinal fermentation of grain dietary fibre and associated effects on gut-mediated metabolic health, such as immunological health and adipose tissue function. The hypothesis was that whole grain products maintain their original beneficial health effects and may be better tolerable when the bran is technologically modified. Additionally, it was hypothesized that gut-mediated bioavailability of plant cell wall compounds and their metabolites affect the metabolic health through their immunomodulatory effects.